Prognostic Cancer Model
9
5
5
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Validation of RCC Predicting Model With Emulated-target Trial
DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
Genomic Signatures for Patients With Initially Unresectable Colorectal Liver Metastases
Nutrition Assessment in Advanced Cancer Patients
Colorectal Cancer Dataset in Xijing Hospital From 2011
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
Prognostic Significance of ctDNA in HL
New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer